Filing Flows › Amgen (AMGN) › Q3 2026
Amgen (AMGN) Q3 2026 earnings results (third quarter 2026)
10-Q filed Nov 4, 2026
Amgen (AMGN) reported revenue of $10.4B for the third quarter 2026 (Q3 2026), +8% from a year earlier and +3% from the quarter before. Operating margin was 35.8%, net earnings $3.9B (37.3% of revenue).
Amgen, Q3 2026: revenue $10.4B (+8% year over year), operating margin 35.8%, net earnings $3.9B, operating cash flow $4.2B. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $10.4B | +3% | +8% |
| Operating profit | $3.7B | +6% | +47% |
| Net earnings | $3.9B | +63% | +20% |
| Operating cash flow | $4.2B | +6% | -9% |
| Free cash flow | $3.7B | +5% | -14% |
What changed
Revenue was $10.4B in Q3 2026, up 8% year over year and up 3% from the previous quarter. Product sales was the largest line at 95% of revenue. Product sales added $0.75B year over year (up 8%), 92% of the total change.
Operating profit was $3.7B, a 35.8% margin (up 9.4 points year over year). Of the extra revenue versus Q3 2025, 147% reached operating profit, above the 26% margin then. Total costs fell 5% while revenue rose 8%. The fastest-growing cost line was Research & development (+11%). Net earnings were $3.9B, up 20% year over year. The effective tax rate was 17.5%. Non-operating items added $1.0B, 21% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was $4.2B (down 9% year over year), 110% of net earnings. Non-cash charges added back $1.1B of depreciation and amortization and $0.13B of share-based compensation. Working capital and other items used $0.87B. Capital expenditures of $0.59B left free cash flow of $3.7B.
Questions
What was Amgen's revenue in the third quarter 2026?
Amgen (AMGN) reported revenue of $10.4B for the third quarter 2026 (Q3 2026), +8% from a year earlier and +3% from the quarter before.
Was Amgen profitable in the third quarter 2026?
Operating profit was $3.7B (35.8% of revenue) and net earnings $3.9B.
Source: Amgen 10-Q on SEC EDGAR.